AlphaQuest LLC Sells 19,154 Shares of MiMedx Group, Inc $MDXG

AlphaQuest LLC decreased its position in MiMedx Group, Inc (NASDAQ:MDXG) by 36.9% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 32,744 shares of the company’s stock after selling 19,154 shares during the period. AlphaQuest LLC’s holdings in MiMedx Group were worth $200,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. CWM LLC grew its holdings in shares of MiMedx Group by 63.8% in the second quarter. CWM LLC now owns 4,857 shares of the company’s stock worth $30,000 after purchasing an additional 1,892 shares during the last quarter. Virtus Advisers LLC bought a new position in shares of MiMedx Group in the first quarter worth approximately $40,000. Legato Capital Management LLC bought a new position in shares of MiMedx Group in the first quarter worth approximately $101,000. AQR Capital Management LLC grew its holdings in shares of MiMedx Group by 42.6% in the first quarter. AQR Capital Management LLC now owns 14,374 shares of the company’s stock worth $109,000 after purchasing an additional 4,296 shares during the last quarter. Finally, Allianz Asset Management GmbH bought a new position in shares of MiMedx Group in the first quarter worth approximately $128,000. Institutional investors own 79.15% of the company’s stock.

MiMedx Group Stock Up 3.4%

Shares of MiMedx Group stock opened at $7.65 on Monday. The company has a current ratio of 4.39, a quick ratio of 3.90 and a debt-to-equity ratio of 0.08. The company’s fifty day simple moving average is $6.99 and its two-hundred day simple moving average is $6.79. The company has a market cap of $1.13 billion, a P/E ratio of 28.33 and a beta of 1.73. MiMedx Group, Inc has a 12-month low of $5.79 and a 12-month high of $10.14.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings data on Monday, November 13th. The company reported ($0.03) EPS for the quarter. The firm had revenue of $67.69 million for the quarter. MiMedx Group had a net margin of 10.38% and a return on equity of 28.35%. Research analysts anticipate that MiMedx Group, Inc will post 0.3 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently issued reports on MDXG. Cantor Fitzgerald raised their target price on shares of MiMedx Group from $11.00 to $12.00 and gave the stock an “overweight” rating in a report on Thursday, July 31st. Weiss Ratings reissued a “hold (c)” rating on shares of MiMedx Group in a research report on Wednesday, October 8th. Finally, Wall Street Zen raised shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a research report on Sunday. One equities research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $12.00.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.